Target Name: VWA3B
NCBI ID: G200403
Review Report on VWA3B Target / Biomarker Content of Review Report on VWA3B Target / Biomarker
VWA3B
Other Name(s): VWA domain-containing protein 3B | Von Willebrand factor A domain-containing 3B | Von Willebrand factor A domain containing 3B, transcript variant 1 | von Willebrand factor A domain containing 3B | VWA3B variant 1 | Von Willebrand factor A domain-containing protein 3B (isoform 1) | MGC26733 | FLJ32686 | von Willebrand factor A domain-containing protein 3B | Von Willebrand factor A domain-containing protein 3B | VWA3B_HUMAN | SCAR22

VWA3B: A Potential Drug Target and Biomarker

VWA3B (VWA domain-containing protein 3B) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function make it an attractive target for drug development.

Structure and Function

VWA3B is a 21-kDa protein that is expressed in various tissues and cells in the body. It is composed of 214 amino acid residues and has a molecular weight of 21.9 kDa. The protein is localized to the endoplasmic reticulum (ER) and can be expressed and purified in a variety of cell types.

The VWA3B protein is characterized by its unique structure. It has a distinct N-terminus that is rich in acidic amino acids, a conserved N-terminal region, and a unique C-terminus that is rich in basic amino acids. The VWA3B protein also has a unique topology, with the N-terminus and C-terminus being connected by a long amino acid tail.

The VWA3B protein functions as a negative regulator of the Wnt signaling pathway. Wnt signaling is a critical signaling pathway that plays a role in the development and maintenance of tissues and organs, including the nervous system and cancer. The VWA3B protein is a negative regulator of the Wnt signaling pathway, which means that it inhibits the activity of the Wnt signaling pathway.

The VWA3B protein is also known as Wilms' tumor 1 (WT1) gene product. It is a tumor suppressor gene that has been implicated in the development of various types of cancer, including neuroblastoma, Wilms' tumor, and hepatocellular carcinoma. The VWA3B protein has also been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Drug Targeting

The VWA3B protein is a potential drug target due to its unique structure and function. Its N-terminus and C-terminus make it a good target for small molecules that can modulate its activity. The VWA3B protein is also known to have a high degree of cross-reactivity, which means that it can be modulated by a variety of small molecules.

One potential drug that may target the VWA3B protein is the small molecule, K-5528, which is a inhibitor of the DNA-binding activity of the VWA3B protein. K-5528 has been shown to inhibit the activity of the VWA3B protein and has been shown to be effective in preclinical studies in modulating the activity of the VWA3B protein.

Another potential drug that may target the VWA3B protein is the small molecule, JS-424, which is a inhibitor of the VWA3B protein's activity as a negative regulator of the Wnt signaling pathway. JS-424 has been shown to be effective in preclinical studies in modulating the activity of the VWA3B protein.

Biomarker

The VWA3B protein is also a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The VWA3B protein is expressed in various tissues and cells in the body and can be used as a protein biomarker for these diseases.

The VWA3B protein is a potential drug target due to its unique structure and function. The VWA3B protein is also a potential biomarker for

Protein Name: Von Willebrand Factor A Domain Containing 3B

The "VWA3B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VWA3B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

VWA5A | VWA5B1 | VWA5B2 | VWA7 | VWA8 | VWC2 | VWC2L | VWCE | VWDE | VWF | VXN | WAC | WAC-AS1 | WAKMAR1 | WAKMAR2 | WAPL | WARS1 | WARS2 | WARS2-AS1 | WAS | WASF1 | WASF2 | WASF3 | WASF4P | WASF5P | WASH complex | WASH2P | WASH3P | WASH4P | WASH5P | WASH6P | WASH7P | WASH8P | WASHC1 | WASHC2A | WASHC2C | WASHC3 | WASHC4 | WASHC5 | WASIR1 | WASL | WAVE1 complex | WBP1 | WBP11 | WBP11P1 | WBP1L | WBP2 | WBP2NL | WBP4 | WDCP | WDFY1 | WDFY2 | WDFY3 | WDFY3-AS2 | WDFY4 | WDHD1 | WDPCP | WDR1 | WDR11 | WDR11-DT | WDR12 | WDR13 | WDR17 | WDR18 | WDR19 | WDR20 | WDR24 | WDR25 | WDR26 | WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7 | WDR70 | WDR72